Skip to main content

Table 1 Outcomes before and after run-in medication (all patients)

From: Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial

  Screening1) End of run-in1) Change from screening to end of run-in2)
Dose level after run-in
 maximum dose 76% 29/38
 step 3 dose 18% 7/38
 step 2 dose 5% 2/38
Systolic blood pressure [mmHg] 111 ± 13 n = 41 102 ± 14 n = 38 −9 [−13 to −5]* n = 37
Echocardiography
 Left ventricle fractional shortening [%] 35 ± 3 n = 42 36 ± 4 n = 38 0 [−1 to 2] n = 38
Electrocardiogram (ECG)
 Ventricular heart rate [beats/min] 97 ± 14 n = 41 88 ± 16 n = 38 −9 [−13 to −4]* n = 37
Holter-Electrocardiogram (Holter-ECG)
 Ventricular heart rate [beats/min]:
 minimum 73 ± 10 n = 38 69 ± 11 n = 35 −2 [−6 to 2] n = 34
 maximum 140 ± 15 n = 38 129 ± 15 n = 35 −11 [−16 to −6]* n = 34
 mean 101 ± 13 n = 38 93 ± 11 n = 35 −8 [−13 to −3]* n = 34
Heart rate variability (Holter ECG)
 mean NN [ms] 574 ± 122 n = 23 627 ± 140 n = 21 52 [24 to 81]* n = 19
 SDNN [ms] 85 ± 23 n = 22 97 ± 29 n = 21 12 [3 to 21]* n = 19
 SDANN [ms] 69 ± 24 n = 23 73 ± 24 n = 21 0 [−12 to 13] n = 20
 ASDNN [ms] 45 ± 18 n = 22 57 ± 21 n = 21 11 [5 to 18]* n = 19
 rMSSD [ms] 35 ± 18 n = 24 46 ± 23 n = 22 9 [−1 to 18] n = 21
 pNN50 [%] 9 ± 8 n = 24 15 ± 13 n = 21 5 [1 to 10]* n = 20
  1. * difference is statistically significant
  2. 1) Data are %, x/n or mean ± SD, n
  3. 2) Data are mean change [95% confidence interval], n